Table 2.

In vivo activity of BRACO19 against various cancer cell lines.

Cell Lines	Tissue Type	IC50	References
MCF7	Breast cancer (human)	2.5 μM	[55,56]
A549	Lung cancer (human)	2.4 μM	[55,57]
DU145	Prostate cancer (human)	2.3 μM	[55,58]
HT-29	Colon cancer (human)	2.7 μM	[55,59]
HGC-27	Gastric carcinoma	2.6 μM	[55,60]
A2780	Ovarian cancer (human)	2.5 μM	[55,61]
WI-38	Lung fibroblast (human)	10.7 μM	[55,62]
IMR90	Lung fibroblast (human)	>25 μM	[55,63]
U87	Glioblastoma (human)	1.45 μM	[64,65]
U251	Glioblastoma (human)	1.55 μM	[64]
SHG-44	Glioma (human)	2.5 μM	[64]
UXF1138L	Uterus carcinoma (human)	2.5 μM	[66]
CH1	Lymphoma (mouse)	10.1 μM	[67]
SKOV3	Ovarian cancer (human)	13.0 μM	[67,68]
CLL	Chronic lymphocytic leukemia	80 μM	[69,70]
AML	Acute myeloid leukemia	80 μM	[70]
--	Prolymphocytic leukemia	80 μM	[70]